Nevolat (Liraglutide)

Liraglutide, the active ingredient in Nevolat, is a GLP-1 receptor agonist presented as a subcutaneous injection for subcutaneous use. It is indicated for the treatment of type 2 diabetes mellitus and for chronic weight management in adults.

GNH USA supplies Nevolat as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU quality standards, is manufactured under strict GMP conditions, and our distribution network ensures timely delivery and regulatory compliance across multiple regions.

Liraglutide is a GLP-1 receptor agonist used in metabolic disorders.

- Type 2 diabetes mellitus: improves glycaemic control by enhancing insulin secretion and lowering glucagon. - Obesity (chronic weight management): promotes sustained weight loss through appetite reduction. - Cardiovascular risk reduction in T2DM with established CVD: lowers incidence of major adverse cardiovascular events.

Liraglutide may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Nausea - Vomiting - Diarrhoea - Constipation - Headache - Injection‑site reactions

Serious or Rare Side Effects: - Pancreatitis - Gallbladder disease (cholelithiasis, cholecystitis) - Severe hypoglycaemia (especially with insulin or sulfonylureas) - Thyroid C‑cell tumours (observed in rodent studies) - Anaphylactic reactions - Acute renal impairment

When prescribing liraglutide, clinicians should consider several safety precautions.

- Renal function: monitor in patients with moderate to severe renal impairment. - Thyroid disease: avoid in individuals with a personal or family history of medullary thyroid carcinoma or MEN 2. - Pancreatitis: discontinue if signs or symptoms of pancreatitis develop. - Pregnancy and lactation: safety not established; use only if potential benefit justifies risk. - Drug interactions: review concomitant medications for hypoglycaemia risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Liraglutide can affect the activity of other medicines; some combinations require avoidance while others need monitoring.

Major Interactions (Avoid): - Insulin: increased risk of severe hypoglycaemia. - Sulfonylureas: heightened hypoglycaemia potential.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR values. - Oral contraceptives: may reduce hormonal efficacy. - Other GLP‑1 receptor agonists: additive effects on gastrointestinal tolerance.